Martin Imaging

By expanding access to this cutting-edge technology, Martin Imaging, Inc. is seeking to improve the standard of care for several currently underserved populations, particularly women, for whom the current generation of technologies is inadequate for proper diagnosis. Positron Emission Tomography (PET) Myocardial Perfusion Imaging (MPI) is the preferred test when compared to other methods of cardiac assessment due to superior image quality, significantly lower radiation exposure, the ability to identify and quantify risk, and the ability to successfully guide therapy in patients with known or suspected coronary artery disease (CAD). The high sensitivity, specificity and diagnostic accuracy allows PET MPI to outperform other non-invasive approaches used to evaluate disease, especially in women, obese patients and those who have previously undergone Coronary Artery Bypass Grafts (CABG).

Despite the superior performance of PET MPI in all patient types as a strong prognostic and risk stratification tool, it is still significantly underutilized as a modality, due to the limited number of Cardiac PET programs currently in existence throughout the United States. This low adoption rate continues to limit access to care and testing for patients who might otherwise benefit from a PET MPI. In addition to cardiology, PET imaging is an important diagnostic, planning and treatment tool for oncology and neurology. While such procedures are widely used in hospital and academic settings, they remain underutilized in outpatient office settings, with limited access in the rural and community settings.

Nuclear cardiologists in private or integrated practices, neurologists specializing in the aging brain/memory clinics, oncologists with older systems looking to upgrade to newer advanced technologies, and radiation oncologists looking to bring PET/CT imaging for treatment planning and staging to their current radiation therapy setting, all benefit from the improved patient outcomes.

Company’s Keywords: